Biogen Idec, Inc. (BIIB) Misses Q2 EPS by 1c, Sales Beat; Guides FY11
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $220.83 -1.64%
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +4.3%
Financial Fact:
Selling, general and administrative: 462.7M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Biogen Idec, Inc. (NASDAQ: BIIB) reported Q2 EPS of $1.36, $0.01 worse than the analyst estimate of $1.37. Revenue for the quarter came in at $1.21 billion versus the consensus estimate of $1.18 billion.
Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.
Sees FY11 adj-EPS above $5.70, which compares to the Street estimate of $5.85.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB) PT Raised to $245 at Piper Sandler
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
- Guidewire Software (GWRE) Tops Q4 EPS by 6c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
